About us


The Liverpool group has been at the forefront of pharmacological research of anti-infective drugs. We have developed innovative experimental approaches to clarify compound distribution , through pharmacokinetic, pharmacogenetic, modelling and molecular- based studies involving national and international collaborations such as John Hopkins University, USA; University of Nebraska, USA; University of Cape Town, South Africa; University of Turin, Italy; Chelsea and Westminster Hospital, UK; University of Cologne, Germany; Basel University, Switzerland; University of Chile, Santiago, Chile; Makerere University, Kampala, Uganda Clinton Health Access Initiative, ViiV Healthcare, GlaxoSmithKline, Janssen Ltd, Merck & Co., Pfizer, Abbott and Boehringer Ingelheim.


David Back

David Back is a Professor of Pharmacology at the University of Liverpool and has worked in the area of Pharmacokinetics and drug –drug interactions for more than 30 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and has authored ~400 publications. He is a former Editor of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology.





Andrew Owen

Andrew Owen, Ph.D. FSB is a Professor in the Department of Molecular and Clinical Pharmacology. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. Professor Owen has contributed to over 110 original research and review publications, book chapters and patent applications. In recent years, research funding has been secured from the Medical Research Council, Engineering and Physical Sciences Research Council, US National Institutes of Health and the British Society for Antimicrobial Chemotherapy. He is Chair of the British Society for Nanomedicine. (www.BritishSocietyNanomedicine.org), a fellow of the Society of Biology and a member of the Nanomed Focus Group Steering Committee, British Pharmacological Society and Critical Path to TB Drug Regimens. Professor Owen is also a member of the editorial board for Nanomedicine: nanotechnology, biology and medicine.



Marco Siccardi

Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He was recently appointed as a Lecturer in Nanomedicine across the faculties of Health & Life Sciences and Science & Engineering at the University of Liverpool. He has authored >70 peer reviewed publications, presenting his findings at several national and international congresses. His research interests focus on physiologically-based mathematical models to investigate the distribution of traditional formulations and nanoparticles in virtual patients and simulate the outcome of various clinical scenarios.




Neill Liptrott

Dr Liptrott has a background in pharmacology, immunology and molecular cell biology and in 2015 was awarded a tenure track fellowship within the department of Molecular and Clinical Pharmacology at the University of Liverpool and heads the nanotechnology biocompatibility research programme. Dr Liptrott has also worked as a guest researcher at, and continues to collaborate with, the National Institutes of Health (NIH) National Cancer Institute’s (NCI) Nanotechnology Characterisation Laboratory (NCL) based in Frederick, Maryland, USA. Dr Liptrott is also a member of the Executive Board, Core Expert Team (CET) and assay group leader for immunotoxicity and haematotoxicity of the recently established European Nanomedicine Characterisation Laboratory (EU-NCL), funded by the European Commission (Horizon 2020). Dr Liptrott leads the University of Liverpool work packages on nanoparticle biocompatibility and structure-activity relationships. His research is focused on investigating the biological interactions of conventional (small molecules) as well as novel therapeutics (nanomaterials and cell therapies) which includes assessment of their biocompatibility and immunological safety. The aim of this work is to develop an understanding of the interaction of these therapies with immunological and haematological systems which is vital to preclinical evaluation as well enabling future rational design of nanomaterials. Additionally, Dr Liptrott has an interest in developing novel techniques and in vitro systems to further investigate these relationships.